The ribonucleoprotein enzyme telomerase is active in most immortal cell lines, most tumors and all tumor-derived cell lines. The enzyme is important because it prevents continual shortening of telomeres and therefore plays a significant role in chromosome maintenance. In man, telomerase is not active in most somal cells with finite lifespans. Using the SV40 T antigen we immortalized and transformed to fully tumorigenic a human fibroblast cell strain. We wished to determine when telomerase was activated during this progression to tumorigenicity. Using the PCR-based TRAP assay we found that eight of eight immortal cell lines that were either not tumorigenic or rarely formed tumors were telomerase positive at the time of inoculation. Additionally, 10 of 11 newly immortal cell lines contained telomerase activity within the first 25-33 population doublings after crisis. None of the precrisis cells from which these immortal cells were derived were positive for telomerase activity. Thus we found that telomerase activation is not the final in vivo step in the transformation of these cells and the window of activation is usually near the escape from crisis or M2. These results strengthen the hypothesis that telomerase activation may allow the rare cell to escape from crisis in those immortal cell populations dependent on telomerase for telomere maintenance.
Introduction
The ends of human chromosomes, called telomeres, are composed of a six nucleotide repeating unit (TTAGGG) n with associated proteins and probably serve a functional role in maintaining the structural integrity of chromosomes (\-4) . It has been hypothesized that the loss of telomeric repeats during successive cell divisions triggers cellular senescence (5) (6) (7) (8) (9) (10) . Thus telomere shortening may act as a molecular counter that determines the lifespan of a mortal cell.
All immortal cells examined thus far can maintain telomeric repeats above a minimal level, indicating that telomere maintenance is necessary for immortality (10, 11) . In most immortal cells telomere length can be maintained by the enzyme telomerase, which adds telomeric repeats to the ends of human chromosomes (11, 12) . This enzyme is active in all tumorderived cell lines and most tumor tissues, yet most mortal somatic tissues do not have detectable enzyme activity (11) . Because a tumor is the result of multiple mutations widiin a lineage of cells, it is difficult to determine retrospectively when telomerase became active in that lineage. Avilion et al.
•Abbreviations: HEK, human embryonic kidney; CPD, cumulative population doublings; Ml, mortality stage 1; M2, mortality stage 2; TRAP, telomeric repeat amplification protocol; PMSF, phenylmethylsulfonyl fluoride.
have reported the existence of a single human embryonic kidney (HEK*) cell line that contains telomerase activity during crisis, indicating that telomerase activation may coincide with immortalization in cells that maintain telomeres by telomerase (13) . To determine the role telomerase plays in tumorigenesis it is important to identify when it is activated.
Normal human fibroblasts have a defined proliferative capacity of ~75 cumulative population doublings (CPD) (14, 15) . Senescence or mortality stage 1 (Ml) has recently been shown to be associated with increased expression of the DNA damageresponsive p53 protein (16) . It has been postulated that critically short telomeres may be analogous to DNA damage and through unknown mechanism(s) trigger p53 and subsequent cell cycle arrest (8) . The viral oncoproteins that bind and inactivate p53 result in Ml bypass and an extended lifespan (17, 18) . After an extended lifespan the cells enter a second proliferative blockade called mortality stage 2 (M2) or crisis, which is characterized by excessive cell death (17, 19) . Escape from crisis occurs at very low frequency (~ 1 cell in 3 000 000) in fibroblasts expressing the SV40 T antigen (20, 21) . The molecular basis that allows this rare resumption of growth is not understood. It has been hypothesized that the activation of telomerase may be responsible for the infrequent escape from crisis (9) .
We wished to determine when during tumorigenesis telomerase was activated in SV40 T antigen-positive immortal human fibroblasts. We assayed telomerase activity using the telomeric repeat amplification protocol (TRAP) assay (22) . Precrisis (mortal) cells, newly immortal cells, high passage (immortal) cells that were used for tumorigenicity assays and resulting tumor-derived cells were tested. We found that in all (eight of eight) cell lines tested for tumorigenicity, telomerase was activated prior to injection into nude mice. Therefore, telomerase activation was not the transforming step that occurred in vivo. Ten of 11 newly immortal cell lines had telomerase activity and none of the precrisis cell strains had detectable activity. Therefore, the activation of telomerase occurred frequently during or immediately after crisis.
Materials and methods

Cells and culture conditions
Cell lineages, plasmids and transfections were as previously described (18, 21) . Briefly, the HSF 43 human diploid fibroblast parental strain was electroporated with various SV40 T antigen constructs and colonies were selected with medium containing G418 (Gibco BRL). CT lineages express SV40 T antigen only, E lineages express SV40 large T and small t antigens and SV lineages express SV40 T and t antigens and have the SV40 origin of replication (18, 21) . Eight T antigen-positive precrisis cell strains, 11 newly immortal cell lines, eight high passage immortal cell lines that were injected into nude mice and representative tumors derived from them were thawed and cultured (Figure 1; 21 ). Cells were cultured in a MEM (Gibco BRL) supplemented with 109b fetal bovine serum, 50 U/ml penicillin (Gibco BRL) and 50 Hg/ml streptomycin (Gibco BRL) in a 5% CO 2 incubator Tumor-derived cells from nude mice were passaged in 0.4 mg/ml G418 (Gibco BRL) for al least two passages prior to lysis in order to ensure no contaminating mouse cells were present. Adenovirus-immortalized 293 cells (ATCC CRL 1573) known to have active telomerase were cultured as above (10,22). 
Cell extract preparations
Cells were either plated onto two 150 mm diameter tissue culture dishes or two T75 cm 2 tissue culture flasks and grown to near confluence. Cells were harvested at 4°C by scraping or trypsinization (Gibco, BRL) and pelleted by centrifugation at 1800 g. No variation in telomerase activity was observed between cells which were scraped versus cells which were treated with trypsin (data not shown). Cell pellets were washed in cold phosphate-buffered saline (2.7 mM KC1, 1.5 mM KH 2 PO 4 , 137 mM NaCl, 8 mM Na 2 HPO 4 ), pelleted and resuspended in ice-cold wash buffer [10 mM HEPES-KOH, pH 7.5, 1 mM MgCl 2 , 10 mM KCI, 1 mM dithiothreitol, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF)] and pelleted at 4°C The cells were then resuspended in 20 |il lysis buffer (10 mM Tns-HCI, pH 7.5, 1 mM MgCl z 1 mM EGTA, 0.1 mM PMSF, 5 mM P-mercaptoethanol, 0.59b CHAPS, 10% glycerol) per 10* cells. This suspension was incubated for 30 min on ice and then centnfuged at 100 000 g for 35 min at 4°C. The supernatant was aliquoted, quick frozen and stored at -70°C. The protein concentrations were determined by the Bradford protein assay (Coomassie Protein Assay; Pierce).
TRAP assay
The TRAP assay was performed as previously described (22) with some minor modifications. Briefly, 50 |il reactions contained 1 X TRAP reaction buffer (20 mM Tris-HCl, pH 8, 1.5 mM MgCl 2 , 63 mM KCI, 0.005% Tween 20, 1 mM EGTA), 50 HM each dNTP, 0.1 ug TS primer, 0 1 mg/ml BSA, 2 u.Ci [oe-32 P]dGTP (10 uCi/nl) and 6 ng CHAPS cell extract (1-3 |il). After incubation at room temperature for 30 min, 2 U Primezyme (Biometra) were added. Reactions were then heated to 90°C for 1 min and 0.1 ng CX primer was added per reaction. Telomerase extension products were amplified by PCR in a thermocycler at 94°C for 30 s, 50°C for 30 s and 72°C for 45 s, for a total of 28 cycles. PCR products were resolved on a 10% non-denaturing polyacrylamide gel for 3.5 h at 250 V. TRAP products were visualized by autoradiography with exposure times of between 8 and 16 h. Positive control 293 cells were assayed in parallel with every experiment. For RNase pretreatments of cell extracts 1 |il 10 mg/ml RNase (Boehringer Mannheim) was added to 5 ul of each extract and incubated at room temperature for 20 min. For heat pretreatments 5 (il each extract were incubated at 75°C for 20 min. Cells were scored telomerase-positive if a continuous 6 bp ladder was observed from 40 bp upward and the ladder was eliminated by RNase and heat pretreatments (22) .
Results
Parental fibroblasts, transfected SV40 T antigen-positive cell strains, newly immortal cell lines, high passage cells inoculated into nude mice and their tumorigenic descendants (Figure 1 ) were tested for telomerase activity using the TRAP assay (Figures 2 and 3) . The parental HSF 43 and eight precrisis mortal T antigen-positive cell strains were telomerase negative, as expected. Newly immortal cell lines ranged from 25 to 33 population doublings (PD) beyond crisis. The population doubling levels of the high passage cells used for inoculations ranged from 126 to 300 CPD (21) . [The number of population doublings before the cells were considered high passage was variable and depended on an observed increase in growth rate (21) .] All (eight of eight) high passage immortal lines that were thawed at the population doubling levels of inoculation were positive for telomerase activity. No tumors were derived from three of these immortal lineages. All (11 of 11) tumors tested were also telomerase positive, as expected. Ten of 11 newly immortal cell lines were telomerase positive. Interestingly, one newly immortal cell line (E2) did not have telomerase activity (Figure 3 ), but gained activity by the time of inoculation (155 CPD) (data not shown). All other newly immortal cell lines had strong telomerase activity, which could be retained when diluted to 0.6 |J.g protein, indicating that activation was an early event in immortalization (data not shown). Thus, we conclude that telomerase activation is frequently an early event in the acquisition of the immortal phenotype of human fibroblasts and is not the in vivo tumorigenicity step. 
Discussion
Telomerase is active in 100% of all tumor-derived cell lines (11, 22) , 85-90% of primary rumor tissue (9) and 72% of immortal cell lines (22) . This activation is likely involved in tumorigenesis. Therefore, we wished to determine when telomerase activation occurred. For example, our earlier studies showed that there is an in vivo transformation event that allows tumors to arise in nude mice (21) . In those studies, SV40 T antigen-immortalized cells that had been cultured in vitro for many CPD were injected into pre-implanted collagen sponges. Tumors arose at low frequencies with long latencies, if at all. When inoculated into nude mice, the cells from these tumors caused tumors to form rapidly, at high incidence. We postulated that an additional mutation(s) occurred in vivo that represented a final step(s) in the tumorigenic process. Here we show that telomerase activation occurred prior to inoculation and was not the final in vivo transforming event.
Our results support the possibility that telomerase activation and escape from the M2 block are the same event, as suggested by Wright et al. (9) . Counter et al. showed that telomere length is maintained immediately after crisis of HEK cells and more recently Avilion et al. cultured the same parental cell strain through crisis and found that the cells become telomerase positive during crisis (10, 13) . There are several other reports in which the authors did not measure telomerase activity immediately after crisis, but show that telomere shortening was arrested soon after immortalization (23) (24) (25) . Here we confirm that telomerase is active by at least 25-33 CPD after crisis in 10 different cell lines. The intensity of telomerase activity from diluted lysates of all 10 newly immortal clones indicates that telomerase was likely to be active well before the cells were frozen, strongly supporting the possibility that activation occurred during crisis. The absence of varying intensity levels among clones soon after crisis favors the possibility that activation occurred at the same time after immortalization (and possibly at the time of immortalization) for each lineage. If escape from M2 and telomerase activation are concomitant, this will provide important clues about telomerase regulation. For example, it was recently shown that fusions between telomerase-positive immortal cells and normal cells that lack telomerase activity result in hybrids that have repressed telomerase activity, indicating the existence of a trans-dommaxti telomerase inhibitor (9) . The rarity of escape from M2 might suggest that such an inhibitor is autosomal and that loss of both copies of the putative inhibitor gene are required for immortalization. Mixing experiments between telomerase-positive and -negative lysates indicate that if such an inhibitor exists, it does not completely'inhibit telomerase activity under in vitro conditions (10, 22, 26, 27) .
Relatively rare telomerase-negative immortal cell lines exist, yet the mechanism of telomere maintenance in these cell lines is not known (22, 26) . In this report we also show the existence of a telomerase-negative cell line (E2). Interestingly, this cell line expressed detectable telomerase activity later, at the time of inoculation into nude mice. Since most immortal cells described here and by others have telomerase activity, the possibility remains that these cell lines arise by telomerase activation and the rest by developing an alternative mechanism^) of telomere extension. No immortal cells have yet been described that do not have a mechanism to maintain telomere length, indicating that telomere maintenance is an absolute requirement of the immortal phenotype.
A recent report by Klingelhutz et al. suggests that expression of the human papillomavirus type 16 E6 protein can activate telomerase in precrisis (prior to M2) keratinocytes and epithelial cells (28) . In a previous study the authors were not able to immortalize cervical epithelial cells with E6 alone and therefore suggest that E6-mediated activation of telomerase is insufficient for immortalization. E6 alone can immortalize mammary epithelial cells, yet at a lower frequency than E6/ E7 together, suggesting that both the p53 and Rb pathways may be involved in escape from M2 (29) . It has been shown that E6 expression alone can extend the lifespan of keratinocyes (28) . It is possible that mutations which mimic the Rb binding functions of E7 may arise during this extended lifespan. In such rare instances the expression of telomerase would impart additional growth advantages leading to immortalization. Klingelhutz et al. subcloned three cell strains and found that they were telomerase negative, suggesting that only a fraction of cells in the population were expressing telomerase. Since no telomerase-positive clones in this study were isolated and tested for immortalization, it is possible some cells in the population were immortal. Examination of telomerase activation in individual clones as they escape M2 (crisis) will resolve this issue. Kim et al. and Bryan et al. have reported that some SV40 T antigen-immortalized fibroblasts (two of three and nine of 16 respectively) do not have telomerase activity (18, 22) . We found that all of our high passage SV40-immortalized cell lines are telomerase positive. The conditions used for immortalization are generally the same and probably do not account for such discrepancies (18, 22, 26, 30) . We cannot eliminate the possibility that differences between specific parental cell strains influence the reactivation of telomerase in SV40 T antigenimmortalized fibroblasts.
It has been suggested that telomerase activation is a late event in tumorigenesis, because telomeres are often shorter in tumors than surrounding normal tissue and telomerase activity is not usually observed until the late stage of progression of the disease (11, 31) . Because tumor formation requires multiple mutations, it is likely that telomerase imparts a selective advantage to cells by allowing replication of telomeres. Therefore, it is possible that telomerase activation coincides with the immortalization step required for development of most malignant tumors. Although this step can be late in the replicative history of the tumor cell lineage, it may be early in the acquisition of the malignant phenotype.
In summary, we conclude that telomerase activation in S V40 T antigen-immortalized human fibroblasts is an event which occurs during or immediately after crisis and is not responsible for the in vivo transformation to tumorigenicity step observed in nude mice.
